title: [Strategy of therapy for bone metastases of cancer].
abstract: Recently, the importance of cancer-induced bone disease has been recognized. Bone metastases of cancer usually do not have major impacts on prognosis of patients, but skeletal-related events (SRE) markedly aggravate QOL of patients. For bone metastases, multi-disciplinary approaches including drug therapy, orthopedic therapy, radiation therapy, or intervention therapy are necessary. As drug therapy, bone-specific drugs that inhibit osteoclasts such as bisphosphonates, anti-RANKL antibody denosumab have been developed and have shown to decrease SRE and improve QOL. Further development of new bone-specific drugs is ongoing.
authors: Dep. of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan.
authors: Shunji
authors: S
authors: Takahashi
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary* / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D053245:RANK Ligand / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D050071:Bone Density Conservation Agents; D053245:RANK Ligand